# Once-a-day Tacrolimus Conversion Study: The OneTAC Trial

Study · id `cardio:ct-nct02545972` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02545972](<https://clinicaltrials.gov/study/NCT02545972>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02545972

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT02545972. Allocation not applicable; no masking; primary purpose treatment. Start 2016-02 (registry gives no type); primary completion 2018-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT02545972, source copy `cardio:ctgov-nct02545972-2016-09-21`, retrieved 2026-10-26)
- Start date: 2016-02 (registry gives no type) (ClinicalTrials.gov record NCT02545972, source copy `cardio:ctgov-nct02545972-2016-09-21`, retrieved 2026-10-26)
- Primary completion: 2018-11 (anticipated) (ClinicalTrials.gov record NCT02545972, source copy `cardio:ctgov-nct02545972-2016-09-21`, retrieved 2026-10-26)
- Completion: 2019-02 (anticipated) (ClinicalTrials.gov record NCT02545972, source copy `cardio:ctgov-nct02545972-2016-09-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02545972, source copy `cardio:ctgov-nct02545972-2016-09-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02545972-2016-09-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Once-a-day Tacrolimus Conversion Study: The OneTAC Trial
- Acronym: OneTAC
- Condition: Heart Failure
- Intervention (Drug): tacrolimus extended release
- Lead sponsor: Newark Beth Israel Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: 567254fde4b9353a673baac74b922ddb42d121c9f23ccd2446721451d865c73b
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
